<DOC>
	<DOCNO>NCT02429726</DOCNO>
	<brief_summary>Objective study investigate efficacy safety recombinant adenoviral human p53 Gene ( rAd-p53 ) treatment malignant pleural effusion , compare cisplatin . This phase 2 , double blind , randomize , active control study .</brief_summary>
	<brief_title>Recombinant Adenoviral Human p53 Gene Treatment Malignant Pleural Effusion</brief_title>
	<detailed_description>Objective study investigate efficacy safety recombinant adenoviral human p53 Gene ( rAd-p53 ) treatment malignant pleural effusion , compare cisplatin . Study design : phase 2 , double blind , randomize , active controlled.Ninety patient malignant pleural effusion , meet study inclusion criterion none exclusion criterion , randomize 3 treatment group : rAd-p53 , cisplatin , rAd-p53 combine cisplatin . The study endpoint objective response rate , Karnofsky score , effusion-free survival , safety .</detailed_description>
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Pleural Effusion , Malignant</mesh_term>
	<mesh_term>Li-Fraumeni Syndrome</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1. histopathologically diagnosed original cancer malignant pleural effusion ; 2 . 18 year old ; 3. normal test hemogram , blood coagulation , liver kidney function ; 6.signed informed consent form . 4. sign inform consent form 1 . Serious blood coagulation disorder , bleed tendency , platelet &lt; 6 * 1000000000/L ; 2. serious heart , lung function abnormality severe diabetes patient ; 3. active infection ; 4. severe atherosclerosis ; 5 . AIDS patient ; 6. serious thrombotic embolic event within 6 month ; 7. renal insufficiency require hemodialysis peritoneal dialysis ; 8. pregnant lactate woman ; 9. mental disorder disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>malignant pleural effusion , p53 gene therapy , cisplatin</keyword>
</DOC>